Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL

NCT07389356 | Not Yet Recruiting

• 1 other identifier: CSPC-DED-DLBCL-K16
• Study Type: interventional
• Target: 70
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study was a multicenter, open, randomized controlled, phase II clinical study. Is expected in 70 cases of late relapsed diffuse large B cell lymphoma, were randomly assigned to receive mitoxantrone liposomes modified R - MINE plan or R - GemOx treatment. Each cycle was 3 weeks (21 days) for a total of 4 cycles. Subjects assigned to each signed informed consent to screening, screening, in the center of the study determined in accordance with the order signed informed consent. Before the start of the trial, the number of random seeds was set by the statistician, and the block randomization method was used to generate the subject random table using R 4.3.3 (or above). The random ratio between the modified R-mine group and the R-Gemox group was 1:1. After the investigator determined that the subjects were screened successfully, the subjects were randomly numbered according to the order in which the eligible subjects were screened successfully. The intervention was performed by the principal investigator or by someone designated by the principal investigator. Study includes screening period (the first 28 days), treatment period (plan 4 cycles, treatment after 2 cycles enhanced CT/MRI or PET - CT mid-term efficacy, PET - CT curative effect evaluation) after treatment, follow-up (follow-up curative effect, safety and survival follow-up follow-up). Participants provided written informed consent and underwent baseline examinations during the screening period. Participants who met the inclusion criteria and none of the exclusion criteria entered the treatment period. All the study participants completed protocol-specified examinations during the course of treatment to observe efficacy and safety. The end of the treatment period was followed by the follow-up period.

Conditions

DLBCL - Diffuse Large B Cell Lymphoma

Keywords

DLBCL; Mitoxantrone Hydrochloride liposomal

Outcome Measures

Primary Outcomes (1)

• Complete response rate (CRR)

  Response is assessed according to the lugano criteria.

  every 2 cycles, up to 4 cycles (each cycle is 21 days)

Secondary Outcomes (5)

• Objective response rate (ORR)

  every 2 cycles, up to 4 cycles (each cycle is 21 days)

• Duration of response (DoR)

  2 years

• Progression-free survival (PFS)

  2 years

• Overall survival (OS)

  2 years

• Adverse events (AEs)

  From the start of treatment to 28 days after the end of treatment.

Study Arms (2)

modified R-MINE

EXPERIMENTAL

Drug: Rituximab+Ifosfamide+Mesna+Mitoxantrone hydrochloride liposome+Etoposide

R-GemOx

ACTIVE COMPARATOR

Drug: Rituximab+Gemcitabine+Oxaliplatin

Interventions

Rituximab+Ifosfamide+Mesna+Mitoxantrone hydrochloride liposome+Etoposide DRUG

Rituximab 375 mg/m\^2, d0; Ifosfamide 1.33 g/m\^2, d1-3 (equal dose of mesna rescue); Mitoxantrone hydrochloride liposome 12mg/m\^2, d1; Etoposide 65 mg/m\^2, d1-3; Every 21 days as one cycle, and 4 cycles were planned.

modified R-MINE

Rituximab+Gemcitabine+Oxaliplatin DRUG

Rituximab 375 mg/m\^2, d0; Gemcitabine 1000 mg/m\^2, d1; Oxaliplatin 100 mg/m\^2, d1; Every 21 days as one cycle, and 4 cycles were planned.

R-GemOx

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• They voluntarily participated in the study and signed the informed consent.
• Age 18 or higher;
• Expected survival time for 3 months or more;
• The histopathological diagnosed late relapsed (\> 12 months) diffuse large B cell lymphoma;
• Must have at least a Lugano 2014 standard can be evaluation or measurable lesions: lymph node lesions, measurable lymph nodes should be diameter \> 1.5 cm; Non-lymph node lesions, measurable extranodal lesions should be diameter \> 1.0 cm;
• ECOG score 0 to 2 points;
• Bone marrow function: neutrophil count \>= 1.5 x 10\^9 / L, platelet count \>= 75 x 10\^9 / L, and hemoglobin \>= 80 g/L (neutrophil count may be extended to \>= 1.0 x 10\^9 / L, the platelet count can be extended to \>= 50 x 10\^9 / L, and hemoglobin can be extended to \>= 75 g/L in patients with bone marrow involvement);
• Liver and kidney function: serum creatinine acuities were \<= 1.5 times the upper limit of normal (ULN) value; AST and ALT \<= 2.5 times the ULN(\<= 5 times the upper limit of normal in patients with liver invasion); Total bilirubin \<= 1.5 times the ULN (\<= 3 times the upper limit of normal in patients with liver invasion);
• Blood coagulation function: International standardization Ratio (International Normalized thewire, INR) \<= 1.5 x ULN; Prothrombin Time (PT), Activated PartialThromboplastin Time (APTT) \<= 1.5×ULN (unless receiving anticoagulant therapy, And PT and APTT at screening were within the expected range for anticoagulant therapy).

You may not qualify if:

• Previous history of antitumor therapy meeting any of the following conditions:
• Prior treatment with mitoxantrone or liposomal mitoxantrone;
• Prior treatment with doxorubicin or other anthracyclines, with a total cumulative doxorubicin dose \>360 mg/m² (for other anthracyclines, 1 mg of doxorubicin is equivalent to 2 mg of epirubicin);
• Prior autologous hematopoietic stem cell transplantation within 100 days before the first dose, or a history of allogeneic hematopoietic stem cell transplantation;
• Prior antitumor therapy (including chemotherapy, targeted therapy, hormone therapy, traditional Chinese medicine with antitumor activity, etc.) or participation in other clinical trials involving investigational drugs within 4 weeks or 5 half-lives (whichever is shorter) before the first dose of the study drug.
• Hypersensitivity to any study drug or its components;
• Uncontrolled systemic diseases (e.g., progressive infections, uncontrolled hypertension, diabetes, etc.);
• Cardiac function and diseases meeting any of the following conditions:
• Long QTc syndrome or QTc interval \>480 ms;
• Complete left bundle branch block, complete right bundle branch block with left anterior fascicular block, type II second-degree or third-degree atrioventricular block;
• Severe, uncontrolled arrhythmia requiring medication;
• New York Heart Association Class ≥ III;
• History of acute myocardial infarction, unstable angina, severe unstable ventricular arrhythmia, or any other arrhythmia requiring treatment within 6 months before enrollment; history of clinically significant pericardial disease; or electrocardiographic evidence of acute ischemic or active conduction system abnormalities.
• Active hepatitis B or C infection (hepatitis B surface antigen positive with HBV DNA \>1×10³ copies/mL; HCV RNA \>1×10³ copies/mL);
• Human immunodeficiency virus (HIV) infection (HIV antibody positive);

Sponsors & Collaborators

• The First Affiliated Hospital with Nanjing Medical University: lead

MeSH Terms

Conditions

Dendritic Cell Sarcoma, Interdigitating

Condition Hierarchy (Ancestors)

Histiocytic Disorders, Malignant; Neoplasms by Histologic Type; Neoplasms; Histiocytosis; Lymphatic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Wei Xu

  The first Affiliated Hospital of Nanjing Medical University(JiangSu Province Hospital)

  PRINCIPAL INVESTIGATOR

• Jinhua Liang

  The first Affiliated Hospital of Nanjing Medical University(JiangSu Province Hospital)

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Wei Xu

CONTACT

025-68306034; xuwei10000@hotmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 17, 2025
• First Posted: February 5, 2026
• Study Start: February 25, 2026
• Primary Completion (Estimated): October 30, 2027
• Study Completion (Estimated): December 30, 2029
• Last Updated: February 5, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share